These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 20920042

  • 21. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes.
    Yang Y, Zhang J, Ma D, Zhang M, Hu S, Shao S, Gong CX.
    J Alzheimers Dis; 2013; 37(3):637-48. PubMed ID: 23948890
    [Abstract] [Full Text] [Related]

  • 22. Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice.
    Millar P, Pathak N, Parthsarathy V, Bjourson AJ, O'Kane M, Pathak V, Moffett RC, Flatt PR, Gault VA.
    J Endocrinol; 2017 Sep; 234(3):255-267. PubMed ID: 28611211
    [Abstract] [Full Text] [Related]

  • 23. Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto-Kakizaki rats.
    Wu L, Olverling A, Fransson L, Ortsäter H, Kappe C, Gao X, Sjöholm A.
    Regul Pept; 2012 Aug 20; 177(1-3):92-6. PubMed ID: 22587909
    [Abstract] [Full Text] [Related]

  • 24. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
    Montanya E, Sesti G.
    Clin Ther; 2009 Nov 20; 31(11):2472-88. PubMed ID: 20109994
    [Abstract] [Full Text] [Related]

  • 25. Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease.
    McClean PL, Gault VA, Harriott P, Hölscher C.
    Eur J Pharmacol; 2010 Mar 25; 630(1-3):158-62. PubMed ID: 20035739
    [Abstract] [Full Text] [Related]

  • 26. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.
    Clin Sci (Lond); 1998 Sep 25; 95(3):325-9. PubMed ID: 9730852
    [Abstract] [Full Text] [Related]

  • 27. Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.
    Madsen AN, Hansen G, Paulsen SJ, Lykkegaard K, Tang-Christensen M, Hansen HS, Levin BE, Larsen PJ, Knudsen LB, Fosgerau K, Vrang N.
    J Endocrinol; 2010 Sep 25; 206(3):287-96. PubMed ID: 20508079
    [Abstract] [Full Text] [Related]

  • 28. Liraglutide protects against amyloid-β protein-induced impairment of spatial learning and memory in rats.
    Han WN, Hölscher C, Yuan L, Yang W, Wang XH, Wu MN, Qi JS.
    Neurobiol Aging; 2013 Feb 25; 34(2):576-88. PubMed ID: 22592020
    [Abstract] [Full Text] [Related]

  • 29. Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity.
    Liang Y, Li Z, Liang S, Li Y, Yang L, Lu M, Gu HF, Xia N.
    Nutr Diabetes; 2016 Jan 25; 6(1):e191. PubMed ID: 26807509
    [Abstract] [Full Text] [Related]

  • 30. Liraglutide: from clinical trials to clinical practice.
    Gough SC.
    Diabetes Obes Metab; 2012 Apr 25; 14 Suppl 2():33-40. PubMed ID: 22405267
    [Abstract] [Full Text] [Related]

  • 31. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
    Kusakabe T, Ebihara K, Sakai T, Miyamoto L, Aotani D, Yamamoto Y, Yamamoto-Kataoka S, Aizawa-Abe M, Fujikura J, Hosoda K, Nakao K.
    Am J Physiol Endocrinol Metab; 2012 Apr 15; 302(8):E924-31. PubMed ID: 22275759
    [Abstract] [Full Text] [Related]

  • 32. Characterization of the use of liraglutide for glycemic control in healthy and Type 1 diabetes mellitus suffering dogs.
    Oda H, Mori A, Lee P, Saeki K, Ishioka K, Arai T, Sako T.
    Res Vet Sci; 2013 Oct 15; 95(2):381-8. PubMed ID: 23632200
    [Abstract] [Full Text] [Related]

  • 33. JTT-130, a novel intestine-specific inhibitor of microsomal triglyceride transfer protein, suppresses high fat diet-induced obesity and glucose intolerance in Sprague-Dawley rats.
    Hata T, Mera Y, Tadaki H, Kuroki Y, Kawai T, Ohta T, Kakutani M.
    Diabetes Obes Metab; 2011 May 15; 13(5):446-54. PubMed ID: 21255216
    [Abstract] [Full Text] [Related]

  • 34. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun 15; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

  • 35. Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice.
    Lennox R, Flatt PR, Gault VA.
    Peptides; 2014 Nov 15; 61():38-47. PubMed ID: 25195184
    [Abstract] [Full Text] [Related]

  • 36. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus.
    Vilsbøll T, Brock B, Perrild H, Levin K, Lervang HH, Kølendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T, Madsbad S.
    Diabet Med; 2008 Feb 15; 25(2):152-6. PubMed ID: 18201212
    [Abstract] [Full Text] [Related]

  • 37. An overview of the pharmacokinetics, efficacy and safety of liraglutide.
    Bode B.
    Diabetes Res Clin Pract; 2012 Jul 15; 97(1):27-42. PubMed ID: 22245694
    [Abstract] [Full Text] [Related]

  • 38. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
    Gault VA, Lennox R, Flatt PR.
    Diabetes Obes Metab; 2015 Apr 15; 17(4):403-13. PubMed ID: 25580570
    [Abstract] [Full Text] [Related]

  • 39. Non-glycaemic effects mediated via GLP-1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide.
    Vilsbøll T, Garber AJ.
    Diabetes Obes Metab; 2012 Apr 15; 14 Suppl 2():41-9. PubMed ID: 22405268
    [Abstract] [Full Text] [Related]

  • 40. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
    Ryan GJ, Hardy Y.
    J Clin Pharm Ther; 2011 Jun 15; 36(3):260-74. PubMed ID: 21545609
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.